The value of PET imaging in Parkinson’s disease with cognition impairment
Objective: The purpose of this study was to explore the diagnostic value of PET imaging, plasma biomarkers in the diagnosis of cognitive dysfunction in Parkinson's…Decreased cholinergic activity in specific brain regions associated with slower lower limb visual choice reaction time in Parkinson’s disease: A [18F]-FEOBV PET study
Objective: To investigate the relationship between cholinergic system changes, as measured by vesicular acetylcholine transporters (VAChT) [18F] fluoroethoxybenzovesamicol ([18F] FEOBV) binding in PET, and cognitive performance, measured as…Brain Energetics: Changes in Healthy Aging and Parkinson’s Disease
Objective: To identify in vivo bioenergetic alterations in healthy aging and Parkinson’s disease (PD). Background: PD-related cerebral metabolic alterations have been robustly characterized [1] and…Striatal Dysfunction in Parkinson’s Disease Progression: A 18F-9-fluoropropyl-(+)-dihydrotetrabenazine(18F-AV133) PET Study
Objective: To investigate the patterns of striatal 18F-AV133 uptake in relation to disease progression across different stages of PD and to examine its relationship with…Comparison of Microglial PET Imaging in Parkinson’s Disease, RBD, and Controls with a CSF1R and TSPO Ligand.
Objective: To compare regional binding patterns of microglial PET radioligands: [11C]DPA-713, a TSPO ligand, and [11C]CPPC1, a CSF1R ligand in people with Parkinson’s disease (PD).…Dopaminergic and Synaptic Alterations in SWEDD: Insights from [¹⁸F] FE-PE2I and [¹¹C] UCB-J PET Imaging
Objective: To investigate dopaminergic and synaptic density in SWEDD patients compared to idiopathic Parkinson’s disease (IPD) and healthy controls (HCs). Background: Scans Without Evidence of…Alterations in Basal Ganglia Synaptic Density and Thalamic Gray Matter Volume are associated with Motor Signs in Late Life Depression: an 11C-UCB-J PET/MR study.
Objective: To investigate differences in the association of motor signs with synaptic density, gray matter volume and white matter lesion volume in patients with late…Functional Segregation in Parkinson’s Disease
Objective: We assessed patterns of dopamine (DA) release and striatal activation induced by behavioural tasks involving corticostriatal loops in Parkinson’s disease (PD) and healthy control…18F-Florzolotau PET uncovers the Co-pathological Heterogeneity of Tau Protein in Dementia with Lewy Bodies
Objective: We attempted to reveal the topographical deposition patterns of tau proteins in the living brains of patients with DLB in vivo by virtue of…Comparing 18F-AV133 VMAT2 PET and DATscan as Markers of Parkinson’s Disease Severity and Progression
Objective: Compare VMAT2 PET signal with DATscan at baseline and over time, and evaluate their correlations with MDS-UPDRS III. Background: DATscan is a Parkinson’s disease…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 40
- Next Page »